Happy Tuesday and welcome to another edition of D.C. Diagnosis. Your author is still embarrassingly proud of his #healthpolicyvalentine. He’s also struck by both the House and Senate’s upcoming hearings on why vaccinations are important. As always, send tips and other comments my way: nicholas.florko@statnews.com.
STAT scoop: new details in the generic drug price-fixing probe
Speaking of generic drugs, my colleague Ed Silverman got his hands on an unredacted copy of the complaint that a whole slew of states filed against generic drug makers in 2016, alleging they colluded to fix prices. (The probe has since expanded to 49 states and 17 companies.)
Please, go read Ed’s story, but I can’t help sharing a few juicy details here. Ed describes some pretty salacious conversations between generic drug executives about planned price hikes for the antibiotic Doxycycline, a drug that’s been around since the 1960s and that treats everything from chlamydia to cholera. One sales rep offered to give up a big group contract if another company would agree to keep its price lower, for example.
One fun (or not so fun) coincidence: Rep. Tom Rice (R-S.C.) was particularly flummoxed during last week's Ways & Means hearing about huge price spikes for this exact drug. If anyone has Rep. Rice’s email, please send him Ed’s story. Read more.
One fun (or not so fun) coincidence: Rep. Tom Rice (R-S.C.) was particularly flummoxed during last week's Ways & Means hearing about huge price spikes for this exact drug. If anyone has Rep. Rice’s email, please send him Ed’s story. Read more.
.png)
No hay comentarios:
Publicar un comentario